For the quarter ended December 2024, Alnylam Pharmaceuticals (ALNY) reported revenue of $593.17 million, up 34.9% over the same period last year. EPS came in at $0.06, compared to -$1.10 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $570.11 million, representing a surprise of +4.05%. The company delivered an EPS surprise of +128.57%, with the consensus EPS estimate being -$0.21.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product revenues, net: $450.83 million versus $437.81 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +30.2% change.
- Revenues- Net revenues from research collaborators: $106.95 million versus the eight-analyst average estimate of $106.14 million. The reported number represents a year-over-year change of +40%.
- Revenues- Royalty revenue: $35.39 million versus the eight-analyst average estimate of $27.14 million. The reported number represents a year-over-year change of +107.9%.
- Net Product Revenues- Givlaari: $64.65 million versus the six-analyst average estimate of $68.78 million. The reported number represents a year-over-year change of +9%.
- Net Product Revenues- Oxlumo: $43.57 million versus the six-analyst average estimate of $44.79 million. The reported number represents a year-over-year change of +33.1%.
- Net Product Revenues- Onpattro: $56.10 million compared to the $47.70 million average estimate based on five analysts. The reported number represents a change of -29% year over year.
- Net Product Revenues- Amvuttra: $286.51 million versus the five-analyst average estimate of $280.22 million. The reported number represents a year-over-year change of +63.5%.
Shares of Alnylam have returned +6% over the past month versus the Zacks S&P 500 composite's +3.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
